Presentations by Program

Efficacy and safety of sulbactam-durlobactam (SUL-DUR) versus colistin therapy in patients with Acinetobacter baumannii-calcoaceticus complex (ABC) infections: a global, randomized, active-controlled phase 3 trial (ATTACK)

David Altarac, Robin Isaacs, Subasree Srinivasan, Sarah McLeod, Khurram Rana, Gabrielle Poirier, Andrew Shorr and Keith Kaye (ECCMID, 2022)

In Vitro Activity of Sulbactam-Durlobactam against Recent Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

Sarah McLeod, Samir Moussa, Meredith Hackel and Alita Miller (ECCMID, 2021)

Sulbactam-Durlobactam MIC and Disk Diffusion Quality Control Ranges Using A CLSI M23-A4 Study Design

Sarah McLeod, Nicole Carter and Alita Miller (Microbe, 2021)

Effect Of Susceptibility Testing Conditions On The In Vitro Antibacterial Activity Of Sulbactam-Durlobactam

Nicole Carter, Sarah McLeod and Alita Miller (Microbe, 2021)

Outer Membrane Permeability and Efflux Do Not Limit Antibacterial Activity of Sulbactam-Durlobactamin Acinetobacter baumannii

Nicole M. Carter, Samir H. Moussa, Sarah M. McLeod, Alita A. Miller and Ramkumar Iyer (Microbe, 2021)

Serious Infections Caused by Carbapenem Susceptible and Carbapenem Resistant Acinetobacter baumannii-calcoaceticus Complex – A Retrospective Review

Rana K, Wunderink R, Tsuei B, Rahav G, Kovalchuk E, Koksal I, Maloney K and Srinivasan S (IDWeek 2020)

Sulbactam-Durlobactam (ETX2514) Is Active Against Recent, Multidrug-Resistant Acinetobacter baumannii Clinical Isolates from the Middle East

McLeod S, Moussa S, Hackel M and Miller A (IDWeek 2020)

A Novel β-lactamase Inhibitor (Durlobactam, DUR) and β-Lactams Enhance Susceptibility Against Multidrug Resistant (MDR) Mycobacterium abscessus (Mab)

Dousa KM, Kurz SG, Bethel CR, Taracilla M, Miller AA and Bonomo RA (IDWeek 2020)

In Vitro Activity of Sulbactam-Durlobactam (ETX2514) Against Recent Global Clinical Acinetobacter baumannii-calcoaceticus Complex Isolates

McLeod S, Moussa S, Hackel M and Miller A (IDWeek 2020)

In Vitro Antibacterial Activity of Sulbactam Durlobactam (ETX2514) against 121 Recent Acinetobacter baumannii Isolates from Patients in India

McLeod SM, Mathur T, Hackel M, Wise M, Morrissey I and Miller AA (IDWeek 2019)